Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases

被引：8
|
作者：
Tung, Nadine M.
Im, Seock-Ah
Senkus-Konefka, Elzbieta
Xu, Binghe
Domchek, Susan M.
Masuda, Norikazu
Li, Wei
Armstrong, Anne Caroline
Conte, Pier Franco
Wu, Wenting
Goessl, Carsten Dietrich
Runswick, Sarah
Robson, Mark E.
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[2] Dana Farber Harvard Canc Ctr, Boston, MA USA
[3] Seoul Natl Univ Hosp, Canc Res Inst, Seoul, South Korea
[4] Med Univ Gdansk, Gdansk, Poland
[5] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Dept Med Oncol, Beijing, Peoples R China
[6] Peking Union Med Coll CAMS & PUMC, Beijing, Peoples R China
[7] Univ Penn, Basser Ctr, Philadelphia, PA 19104 USA
[8] Natl Hosp Org, Osaka, Japan
[9] Jilin Univ, Hosp 1, Changchun, Peoples R China
[10] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[11] Univ Padua, Padua, Italy
[12] Ist Oncol Veneto IRCCS, Padua, Italy
[13] AstraZeneca, Gaithersburg, MD USA
[14] AstraZeneca, Macclesfield, Cheshire, England
[15] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.1052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1052
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation (vol 377, pg 523, 2017)
    Robson
    Im
    Senkus
    Domchek
    Masuda
    Tung
    Armstrong
    Wu
    Goessl
    Runswick
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (17): : 1700 - 1700
  • [32] Indirect treatment comparison of the efficacy and safety of olaparib 300 mg tablets BID and talazoparib 1 mg once daily in the treatment of patients with germline BRCA-mutated (gBRCA) HER2-negative metastatic breast cancer.
    McCrea, Charles
    Hettle, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Value for money of putting precision into practice: Germline genetic testing to guide olaparib treatment in HER2-negative metastatic breast cancer
    Tuffaha, Haitham
    Scuffham, Paul
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 64 - 65
  • [34] Efficacy of Moxifloxacin plus Treatment of Physician's Choice in Patients with Metastatic Breast Cancer
    Wang, Xinyue
    Li, JiBin
    Shi, Wei
    Huang, Zhangzan
    Xia, Wen
    Huang, Jiajia
    Su, Yanhong
    Wang, Shusen
    Shi, Yanxia
    Bi, Xiwen
    Yuan, Zhongyu
    ONCOLOGIST, 2020, 25 (10): : E1439 - E1445
  • [35] Prevalence of germline BRCA mutations in unselected Korean patients with HER2-negative breast cancer: A Prospective cohort study
    Ahn, Hee Kyung
    Kim, Jee Hung
    Kim, Mirae
    Park, Seri
    Koh, Su-Jin
    Sohn, Joo Hyuk
    Kang, Myoung Joo
    Jung, Kyung Hae
    Lee, Kyoung Eun
    Lee, Jieun
    Koh, Sung Ae
    Chae, Yee Soo
    Byun, Jae Ho
    Park, In Hae
    Kim, Hee-Jun
    Kim, Jee Hyun
    Kim, Han Jo
    Jung, Joo Young
    Lee, Jung Lim
    Cho, Yoon Young
    Park, Kyong Hwa
    Kim, Ji-Yeon
    Im, Seock-Ah
    Park, Yeon Hee
    CANCER RESEARCH, 2023, 83 (05)
  • [36] Germline variants in non-BRCA homologous recombination genes detected in HER2-negative breast cancer patients
    Postula, K. J. Vogel
    McGill, A. K.
    Sutcliffe, E.
    Murphy, P. D.
    Klein, R. T.
    Hruska, K. S.
    CANCER RESEARCH, 2019, 79 (04)
  • [37] Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
    Shingaki, Sumito
    Kogawa, Takahiro
    Shimokawa, Mototsugu
    Haranol, Kenichi
    Naito, Yoichi
    Kusuharal, Shota
    Fujimoto, Yumi
    Matsubaral, Nobuaki
    Hosono, Ako
    Mukail, Hirofumi
    Onishi, Tatsuya
    Hojo, Takashi
    Mukohara, Toru
    JOURNAL OF CANCER, 2020, 11 (14): : 4099 - 4105
  • [38] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide in patients with HER2-negative metastatic breast cancer
    Ohtani, S.
    Fujihara, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 30 - 30
  • [39] Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
    Iwase, Toshiaki
    Cohen, Evan N.
    Gao, Hui
    Alexander, Angela
    Kai, Megumi
    Chiv, Vivian
    Wang, Xiaoping
    Krishnamurthy, Savitri
    Liu, Diane
    Shen, Yu
    Kida, Kumiko
    Reuben, Alexandre
    Layman, Rachel M.
    Ramirez, David L.
    Tripathy, Debasish
    Moulder, Stacy L.
    Yam, Clinton
    Valero, Vicente
    Lim, Bora
    Reuben, James M.
    Ueno, Naoto T.
    CLINICAL CANCER RESEARCH, 2024, 30 (11) : 2424 - 2432
  • [40] Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
    Blum, Joanne L.
    Laird, A. Douglas
    Litton, Jennifer K.
    Rugo, Hope S.
    Ettl, Johannes
    Hurvitz, Sara A.
    Martin, Miguel
    Roche, Henri H.
    Lee, Kyung-Hun
    Goodwin, Annabel
    Chen, Ying
    Lanzalone, Silvana
    Chelliserry, Jijumon
    Czibere, Akos
    Hopkins, Julia F.
    Albacker, Lee A.
    Mina, Lida A.
    CLINICAL CANCER RESEARCH, 2022, 28 (07) : 1383 - 1390
12345